2021
DOI: 10.1007/s10620-021-07287-6
|View full text |Cite
|
Sign up to set email alerts
|

Troponin C-1 Activated by E2F1 Accelerates Gastric Cancer Progression via Regulating TGF-β/Smad Signaling

Abstract: Background Troponin C-1 (TNNC1) has been previously characterized as an oncogenic gene. Aims This study aimed to reveal the roles of TNNC1 in gastric cancer and the potential underlying mechanisms. Methods TNNC1 siRNAs and TNNC1 overexpression plasmid were used to alter its expression in AGS, MKN45, and HGC-27 cells. CCK-8 assay, colony formation, EdU assay, flow cytometry, transwell assay, and scratch test were conducted to measure the phenotype changes. In vivo effects of TNNC1 silence were confirmed by usin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
0
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 32 publications
0
0
0
Order By: Relevance
“…These ndings suggest E2F1 as a potential therapeutic target for mitigating brosis and preserving cardiac function in cardiovascular diseases. Furthermore, E2F1 interacts with other brosisrelated pathways like TGF-β/Smad (Fang et al, 2022), highlighting its central role in brosis progression and the need for comprehensive anti-brotic therapies.…”
Section: Discussionmentioning
confidence: 99%
“…These ndings suggest E2F1 as a potential therapeutic target for mitigating brosis and preserving cardiac function in cardiovascular diseases. Furthermore, E2F1 interacts with other brosisrelated pathways like TGF-β/Smad (Fang et al, 2022), highlighting its central role in brosis progression and the need for comprehensive anti-brotic therapies.…”
Section: Discussionmentioning
confidence: 99%
“…Our results found downregulation of the gene, which was in line with our findings of antiproliferative activity. There is also evidence in the literature of interaction between Smad3 and members of the E2F family through signaling via the microRNA, miR-618, in head and neck squamous cell carcinoma (HNSCC) (Hui et al, 2016), and through troponin C-1 in gastric cancer (Fang et al, 2022). Smad3 is highly associated with TGF-β signaling (Derynck and Zhang, 2003) and when downregulated, is associated with higher patient survival rate in HNSCC (Xie et al, 2013).…”
Section: Discussionmentioning
confidence: 99%